Clinical Handbook of Psychotropic Drugs for Children and Adolescents

Buch | Spiralbindung
438 Seiten
2023 | 5th edition
Hogrefe Publishing (Verlag)
978-0-88937-625-0 (ISBN)

Lese- und Medienproben

Clinical Handbook of Psychotropic Drugs for Children and Adolescents -
84,95 inkl. MwSt
Quick and comprehensive information on psychotropic drugs for children and adolescents.

- Accurate and up-to-date
- Specific to children and adolescents
- Charts and tables help decision-making
- Icons and full color
The Clinical Handbook of Psychotropic Drugs for Children and Adolescents has become a standard reference and working tool for psychiatrists, pediatricians, psychologists, physicians, pharmacists, nurses, and other mental health professionals.


* Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options
* Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, nursing implications, and much more - all you need to know for each class of drug
* Potential interactions and side effects summarized in comparison charts
* With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
* Clearly written patient and caregiver information sheets for download as printable PDF files


This book is a must for all mental health professionals working with children and adolescents who need an up-to-date, easy-to use, comprehensive summary of all the most relevant information about psychotropic drugs.

New in this edition:


*New chapters on Prescribing Safely and Ethically to Children and Adolescents, Pharmacogenetic Information for Common Psychotropic Drugs, and Aggression Management in Children and Adolescents
*Neuroscience-based nomenclature added to Product Availability tables
*Antipsychotic-Induced Extrapyramidal Side Effect (EPSE) completely revised plus new section on monitoring scales for EPSE
*Anxiolytics section on buspirone and benzodiazepine comparison table revised
*Mood Stabilizers chapter extensively revised
*Natural Health Products comprehensively revised
*New Unapproved Treatments revised, including preliminary evidence for cannabidiol and folinic acid for autism spectrum disorder and ketamine for mood disorder
*New agents include: deutetrabenazine, ethopropazine, lemborexant, lumateperone, orphenadrine, tetrabenazine, valbenazine, viloxazine
*New formulations and trade names include:
Austedo, Caplyta, Dayvigo, Drizalma Sprinkle, Elepsia XR, Eprontia, Evekeo ODT, Gocovri, Hetlioz LQ, Ingrezza, Invega Hafyera, Jornay PM, Loreev XR, Lybalvi, Osmolex ER, Oxtellar XR, Parsitan, Perseris, Qelbree, Qudexy XR, Secuado, Spritam, Tyrvaya, Valtoco

Dean Elbe; BScPharm, PharmD, BCPP; Healthy Minds Centre, Children's & Women's Health Centre of British Columbia, Vancouver, BC, Canada; Lower Mainland Pharmacy Services and Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada. Tyler R. Black; BSc, MD, FRCPC; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada. Ian R. McGrane; PharmD, BCPS, BCPP; Skaggs School of Pharmacy, University of Montana, Missoula, MT, USA. Sabina Choi, BScPharm, PharmD, Victoria Primary Care Network, Island Health, Victoria, BC, Canada.

Prescribing Safely and Ethically to Children and Adolescents
Psychiatric Disorders in Children and Adolescents
Attention-Deficit/Hyperactivity Disorder (ADHD) * Major Depressive
Disorder (MDD) * Disruptive Mood Dysregulation Disorder (DMDD) * Bipolar
Disorder (BD) * Schizophrenia * ANXIETY DISORDERS * Separation
Anxiety Disorder * Generalized Anxiety Disorder (GAD) * Social Anxiety
Disorder * Panic Disorder * Specific Phobia * Obsessive-Compulsive Disorder
(OCD) * TRAUMA- AND STRESSOR-RELATED DISORDERS * Posttraumatic
Stress Disorder (PTSD) * TIC DISORDERS * Tourette's Disorder
* Autism Spectrum Disorder (ASD) * DISRUPTIVE, IMPULSE-CONTROL,
AND CONDUCT DISORDERS * Conduct Disorder (CD)
Oppositional Defiant Disorder (ODD)
Drugs for ADHD
Psychostimulants * Atomoxetine * Comparison of Drugs for ADHD * 2
Agonists * Augmentation Strategies in ADHD
Antidepressants
Selective Serotonin Reuptake Inhibitors (SSRI) * Norepinephrine Dopamine
Reuptake Inhibitor (NDRI) * Serotonin Norepinephrine Reuptake
Inhibitor (SNRI) * Serotonin-2 Antagonists/Reuptake Inhibitors (SARI)
* Serotonin-1A Partial Agonist/Serotonin Reuptake Inhibitor (SPARI) *
Serotonin Modulator and Stimulator (SMS) * Noradrenergic/Specific
Serotonergic Antidepressants (NaSSA) * Nonselective Cyclic Antidepressants
* Monoamine Oxidase Inhibitors * Reversible Inhibitor of
MAO-A (RIMA) * Irreversible Monoamine Oxidase (A&B) Inhibitors
(MAOIs) * Irreversible MAO-B Inhibitor * Effects of Antidepressants on
Neurotransmitters/Receptors * Pharmacological Effects of Antidepressants
on Neurotransmitters/Receptors * Frequency of Adverse
Reactions to Antidepressants at Therapeutic Doses * Antidepressant
Doses and Pharmacokinetics * Switching Antidepressants * Antidepressant
Augmentation Strategies
Electroconvulsive Therapy (ECT)
Antipsychotics
"Second-Generation" Antipsychotics/SGAs * "Third-Generation" Antipsychotic/
TGA * "First-Generation" Antipsychotics/FGAs * Effects
of Antipsychotics on Neurotransmitters/Receptors* Pharmacological
Effects of Antipsychotics on Neurotransmitters/Receptors * Frequency
(%) of Adverse Reactions to Antipsychotics at Therapeutic Doses *
Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting
Injections) * Comparison of Long-Acting IM Antipsychotics * Switching
Antipsychotics * Antipsychotic Augmentation Strategies
Antipsychotic-Induced Extrapyramidal Side Effects (EPSE) and Their
Management
Extrapyramidal Side Effects of Antipsychotics * Treatment Options for
Extrapyramidal Side Effects * Effects on Extrapyramidal Symptoms *
Comparison of Agents for Treating Acute Extrapyramidal Side Effects
* Doses and Pharmacokinetics of Agents for Treating Acute Extrapyramidal
Side Effects
Anxiolytic (Antianxiety) Agents
Benzodiazepines * Comparison of the Benzodiazepines * Buspirone
Hypnotics/Sedatives
Comparison of Hypnotics/Sedatives
Mood Stabilizers
Lithium * Anticonvulsants * Comparison of Anticonvulsants * Frequency
of Adverse Reactions to Mood Stabilizers at Therapeutic Doses
Drugs/Substances of Abuse
Alcohol * Stimulants * Hallucinogens * Opioids * Inhalants/Aerosols
* Sodium Oxybate (Gamma-Hydroxybutyrate - GHB) * Flunitrazepam
(Rohypnol) * Nicotine/Tobacco
Treatment of Substance Use Disorders
Disulfiram * Acamprosate * Naltrexone * Methadone * Buprenorphine
* Pharmacotherapy for Nicotine/Tobacco Use Dependence
Unapproved Treatments of Psychiatric Disorders
Adrenergic Agents * Cholinergic Agents * Dopaminergic Agents * GABA
Agents/Anticonvulsants * Miscellaneous * NMDA Agents
Natural Health Products
Pharmacogenetic Information for Common Psychotropic Drugs
Management of Aggression in Children and Adolescents
Glossary
Drug Use in Pregnancy and Effects on Breast Milk
Patient and Caregiver Information Sheets
Index of Drugs

Erscheinungsdatum
Verlagsort Toronto
Sprache englisch
Maße 11 x 216 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Pädiatrie
Medizin / Pharmazie Medizinische Fachgebiete Psychiatrie / Psychotherapie
Medizin / Pharmazie Pflege
Medizin / Pharmazie Pharmazie PTA / PKA
Medizin / Pharmazie Studium
Schlagworte Paediatric medicine • Psychopharmacology • Psychotropic drugs
ISBN-10 0-88937-625-5 / 0889376255
ISBN-13 978-0-88937-625-0 / 9780889376250
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Inklusive Neonatologie/ Intensivmedizin

von Dietmar Wigger; Markus Stange

Buch | Softcover (2020)
Urban & Fischer in Elsevier (Verlag)
30,00
Grundlagen, Klinik und Praxis

von Ertan Mayatepek

Buch | Hardcover (2023)
Urban & Fischer in Elsevier (Verlag)
129,00